Lugano, Switzerland – September 19, 2024 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, is pleased to announce the appointment of Riccardo Carbucicchio as a new member of its Board of Directors, effective immediately.
Riccardo Carbucicchio has extensive experience in pharmaceutical management. He is currently Chief Executive Officer of NTC Pharma, whose development has been greatly supported by Riccardo’s proven experience in the field.
Previous positions include Head of Partnering of General Medicines and Mature Products at Novartis headquarters in Switzerland and Managing Director of the Italian organization of Bausch + Lomb Italy, where he also led the Pharma business unit in Portugal and Spain.
Riccardo Carbucicchio holds a degree in Economics and Business Administration from Bocconi University of Milan.
Riccardo Braglia, Helsinn Group Executive Chairman, commented: “I am delighted to welcome Riccardo Carbucicchio to Helsinn's Board of Directors and looking forward to his contribution. Based on his many years of experience in the pharmaceutical industry, I’m sure he will provide an invaluable perspective on the opportunities and challenges at Helsinn.”
Commenting on his appointment, Riccardo Carbucicchio said: "Helsinn is highly respected in the industry for the way it collaborates with partners around the world. The team's dedication to improving the quality of life for patients is something I share, and I’m thrilled to work with the entire Board of Directors as we pursue this mission."